Flebogamma (Instituto Grifols SA)
Flebogamma (Instituto Grifols SA) Brand names, Flebogamma (Instituto Grifols SA) Analogs
Flebogamma (Instituto Grifols SA) Brand Names Mixture
- No information avaliable
Flebogamma (Instituto Grifols SA) Chemical_Formula
C6332H9826N1692O1980S42
Flebogamma (Instituto Grifols SA) RX_link
http://www.rxlist.com/cgi/generic2/baygam.htm
Flebogamma (Instituto Grifols SA) fda sheet
Flebogamma (Instituto Grifols SA) msds (material safety sheet)
Flebogamma (Instituto Grifols SA) Synthesis Reference
No information avaliable
Flebogamma (Instituto Grifols SA) Molecular Weight
142682.3
Flebogamma (Instituto Grifols SA) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Flebogamma (Instituto Grifols SA) H2O Solubility
No information avaliable
Flebogamma (Instituto Grifols SA) State
Liquid
Flebogamma (Instituto Grifols SA) LogP
-0.331
Flebogamma (Instituto Grifols SA) Dosage Forms
Solution
Flebogamma (Instituto Grifols SA) Indication
For treatment of immunodeficiencies, thrombocytopenic purpura, Kawasaki disease, gammablobulinemia, leukemia, bone transplant
Flebogamma (Instituto Grifols SA) Pharmacology
Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immune globulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.
Flebogamma (Instituto Grifols SA) Absorption
No information avaliable
Flebogamma (Instituto Grifols SA) side effects and Toxicity
No information avaliable
Flebogamma (Instituto Grifols SA) Patient Information
No information avaliable
Flebogamma (Instituto Grifols SA) Organisms Affected
No information avaliable
